Alercell to Distribute Leukemia Fusion Gene Screening and Genotyping Kit

BOZEMAN, Mont., April 26, 2022 /PRNewswire/ — Alercell, announced today that it will begin distributing a Leukemia Fusion Gene Screening and Genotyping Kit created and manufactured by Zeesan, a longtime partner of Alercell.

Leukemia, commonly known as blood cancer, is a malignant disease of the blood system. The innovative approach of the Leukemia Fusion Gene Kit is to target the gene mutations, the clonogenic gene rearrangements and abnormal gene expression. Fusion genes are one of the most common biomarkers in Leukemia and are caused by chromosome breakage and recombination. More than 200 types of fusion genes have been identified, and about 50% of leukemia patients have fusion gene biomarkers, and different disease subtypes have different fusion gene profiles.

The Zeesan approach allows the screening of up to 55 types of leukemia fusion genes. The screening allows a more precise medication, precisely targeting the relevant genes.  This allows a timely adjustment of treatment schedule and signals potential relapse warnings.

"One valuable aspect is the unique combination of accuracy and speed" said Dr. Alexandre Scheer MD Chief Medical Officer of Alercell. "The approach is not only innovative but could mean tremendous savings in terms of time and money for treating Leukemia. The traditional approach is done through blood tests and bone marrow biopsy, while the Zeesan Leukemia Fusion Gene Screening and Genotyping Kit is a kit that is analyzed through a standard PCR machine". Results can be obtained in a few hours at a fraction of the costs of the traditional approach.   

"Using a genetic approach and using our knowledge of the genome is definitively the medicine of the 21st century," said Frederic Scheer, Alercell CEO. "It is important to give practitioners and patients a fast and affordable solution to all the life-threatening conditions that are ravaging the lives of so many."

The Leukemia Fusion Gene Screening and Genotyping Kit will start as a "RUO" Research Use Only while waiting for the final FDA certification to expand the distribution around the country.


Alercell is a Biotechnology company specialized in infectious diseases, and in-vitro diagnostics tests for cancer, based in Bozeman, Montana with a satellite office in New York City. Created by a group of veterans of medical research, Alercell’s core business is in the discovery, development, distribution, manufacture, and sale of efficient treatment for infectious diseases including the Coronavirus and cancer prevention diagnostic testing. For more information, please visit:

Forward Looking Statements

Certain statements made in this release are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Alercell ‘s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include the inability to complete the proposed business combination or the Extension; the inability to recognize the anticipated benefits of the proposed business combination; costs related to any business combination; Alercell’s ability to manage growth; Alercell’s ability to execute its business plan; the timing of revenues from existing customers, including uncertainties related to the ability of Alercell’s customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Alercell’s and its customers’ businesses; uncertainties related to Alercell’s estimates of the size of the markets for its products; the rate and degree of market acceptance of Alercell ‘s products; the success of other competing products and services that exist or may become available; Alercell’s ability to identify and integrate acquisitions; rising costs adversely affecting Alercell’s profitability; uncertainties related to Alercell’s potential litigation involving Alercell or the validity or enforceability of Alercell’s intellectual property; and general economic and market conditions impacting demand for Alercell’s products and services. Other factors include the possibility that any proposed business combination does not close, including due to the failure to receive required security holder approvals, or the failure of other closing conditions. Alercell does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.


This release shall neither constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

Media Contact
Alercell, Inc.
Mr. Frederic Scheer, CEO

Dr. Alexandre Scheer, Chief Medical Officer

Tel: (406) 233-6434

SOURCE Alercell